Search research articles
Contact Us
Filters
Showing results (81-90 of 96) with videos related to
Page
of 10
Sort By:
Antimicrobial Agents and Chemotherapy
|
March 16, 2011
Pharmacokinetics of anidulafungin in pleural fluid during the treatment of a patient with Candida empyema
Brad Moriyama, Marisa Ditullio, Eleanor Wilson, et al.
Nucleic Acids Research
|
July 22, 2016
APOBEC3 proteins can copackage and comutate HIV-1 genomes
Belete A Desimmie, Ryan C Burdick, Taisuke Izumi, et al.
Annals of Internal Medicine
|
August 9, 2017
Expansion of Treatment for Hepatitis C Virus Infection by Task Shifting to Community-Based Nonspecialist Providers: A Nonrandomized Clinical Trial
Sarah Kattakuzhy, Chloe Gross, Benjamin Emmanuel, et al.
The Journal of Infectious Diseases
|
February 22, 2024
Safety and Immunogenicity of an mRNA-Based RSV Vaccine Including a 12-Month Booster in a Phase 1 Clinical Trial in Healthy Older Adults
Christine A Shaw, Brandon Essink, Charles Harper, et al.
Respiratory Investigation
|
September 10, 2024
Safety and immunogenicity of an mRNA-based RSV vaccine in Japanese older adults aged ≥60 years: A phase 1, randomized, observer-blind, placebo-controlled trial
David Fitz-Patrick, Hanako Mihara, Anthony Mills, et al.
Nature Communications
|
July 3, 2025
Immune correlates analysis of mRNA-1345 RSV vaccine efficacy clinical trial
Chong Ma, Jiejun Du, Lan Lan, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
September 24, 2025
Safety, Tolerability, and Immunogenicity of Revaccination with mRNA-1345, an mRNA Vaccine Against RSV, Administered 12 Months Following a Primary Dose in Adults Aged ≥50 Years
Jaya Goswami, Jose F Cardona, Jorge Caso, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
June 4, 2025
Safety, Tolerability, and Immunogenicity of mRNA-1345 in Adults at Increased Risk for Respiratory Syncytial Virus Disease Aged 18-59 Years
Erick F Mayer, Ann R Falsey, Rebecca Clark, et al.
Infectious Diseases and Therapy
|
November 16, 2024
Leveraging Real-World Evidence to Define Severe RSV Lower Respiratory Tract Disease in Adults
Catherine A Panozzo, Edward E Walsh, Zhen Yang, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
October 28, 2015
Moderate Sustained Virologic Response Rates With 6-Week Combination Directly Acting Anti-Hepatitis C Virus Therapy in Patients With Advanced Liver Disease
Sarah Kattakuzhy, Eleanor Wilson, Sreetha Sidharthan, et al.
Page
of 10
Search research articles
Search
Showing results (81-90 of 96) with videos related to
Sort By:
Page
of 10
Antimicrobial Agents and Chemotherapy
|
March 16, 2011
Pharmacokinetics of anidulafungin in pleural fluid during the treatment of a patient with Candida empyema
Brad Moriyama, Marisa Ditullio, Eleanor Wilson, et al.
Nucleic Acids Research
|
July 22, 2016
APOBEC3 proteins can copackage and comutate HIV-1 genomes
Belete A Desimmie, Ryan C Burdick, Taisuke Izumi, et al.
Annals of Internal Medicine
|
August 9, 2017
Expansion of Treatment for Hepatitis C Virus Infection by Task Shifting to Community-Based Nonspecialist Providers: A Nonrandomized Clinical Trial
Sarah Kattakuzhy, Chloe Gross, Benjamin Emmanuel, et al.
The Journal of Infectious Diseases
|
February 22, 2024
Safety and Immunogenicity of an mRNA-Based RSV Vaccine Including a 12-Month Booster in a Phase 1 Clinical Trial in Healthy Older Adults
Christine A Shaw, Brandon Essink, Charles Harper, et al.
Respiratory Investigation
|
September 10, 2024
Safety and immunogenicity of an mRNA-based RSV vaccine in Japanese older adults aged ≥60 years: A phase 1, randomized, observer-blind, placebo-controlled trial
David Fitz-Patrick, Hanako Mihara, Anthony Mills, et al.
Nature Communications
|
July 3, 2025
Immune correlates analysis of mRNA-1345 RSV vaccine efficacy clinical trial
Chong Ma, Jiejun Du, Lan Lan, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
September 24, 2025
Safety, Tolerability, and Immunogenicity of Revaccination with mRNA-1345, an mRNA Vaccine Against RSV, Administered 12 Months Following a Primary Dose in Adults Aged ≥50 Years
Jaya Goswami, Jose F Cardona, Jorge Caso, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
June 4, 2025
Safety, Tolerability, and Immunogenicity of mRNA-1345 in Adults at Increased Risk for Respiratory Syncytial Virus Disease Aged 18-59 Years
Erick F Mayer, Ann R Falsey, Rebecca Clark, et al.
Infectious Diseases and Therapy
|
November 16, 2024
Leveraging Real-World Evidence to Define Severe RSV Lower Respiratory Tract Disease in Adults
Catherine A Panozzo, Edward E Walsh, Zhen Yang, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
October 28, 2015
Moderate Sustained Virologic Response Rates With 6-Week Combination Directly Acting Anti-Hepatitis C Virus Therapy in Patients With Advanced Liver Disease
Sarah Kattakuzhy, Eleanor Wilson, Sreetha Sidharthan, et al.
Page
of 10